Related Experiment Video
Updated: May 19, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study.
Anna Sebestyén1, Tamás B Sticz, Agnes Márk
11st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. anna@korb1.sote.hu
Summary
Targeting the mammalian target of rapamycin (mTOR) pathway shows promise for treating diffuse large B-cell lymphoma. mTOR activity is prevalent in non-germinal center subtypes, suggesting potential therapeutic benefits but requiring careful patient selection for mTOR inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy with variable treatment responses.
- Targeting the mammalian target of rapamycin (mTOR) pathway is an emerging therapeutic strategy for lymphomas.
- Limited data exists on mTOR activity and its complexes in DLBCL.
Purpose of the Study:
- To investigate mTOR activity and protein expression in DLBCL subtypes.
- To correlate mTOR activity with clinical outcomes and patient survival.
- To assess the potential of mTOR inhibitors in DLBCL treatment.
Main Methods:
- Tissue microarrays from 68 DLBCL biopsies were analyzed.
- Over 700 immunohistochemical stainings assessed mTOR signaling proteins and phosphoproteins.
- Lymphoma classification markers were used to differentiate subtypes.
Main Results:
- Germinal center-derived DLBCL showed minimal mTOR activity.
- Approximately 80% of non-germinal center DLBCL cases exhibited mTOR activity.
- Rictor overexpression, associated with mTOR activity, correlated with significantly worse patient survival.
Conclusions:
- mTOR activity is a hallmark of most non-germinal center DLBCLs, indicating potential sensitivity to mTOR inhibitors.
- Rictor overexpression in conjunction with mTOR activity predicts poor prognosis in DLBCL patients.
- mTOR inhibitors may offer a valuable addition to standard DLBCL therapy, necessitating careful patient and inhibitor selection.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...